News
RVPH
3.480
-5.69%
-0.210
Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment
Healthcare Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment. The FDA accepted a four-week study for brilaroxazine in schizophrenia. Reviva Pharmaceuticals Holdings, Inc. Announced it has gained alignment with the FDA on its program.
Seeking Alpha · 21h ago
Reviva Pharmaceuticals Q4 EPS $(0.35) Misses $(0.32) Estimate
Benzinga · 22h ago
Reviva Pharmaceuticals: Insights from Latest SEC Report
TipRanks · 22h ago
REVIVA PHARMACEUTICALS HOLDINGS- FDA INDICATED IT WILL REQUIRE A LONG-TERM RANDOMIZED WITHDRAWAL STUDY POST-APPROVAL TO SUPPORT MAINTENANCE OF EFFECT
Reuters · 22h ago
REVIVA PHARMACEUTICALS HOLDINGS, INC. - GAINED ALIGNMENT WITH FDA ON ITS REGISTRATIONAL PHASE 3 PROGRAM FOR BRILAROXAZINE IN SCHIZOPHRENIA
Reuters · 22h ago
*Reviva Pharm Holdings 2023 Cash, Cash Equivalents Totaled Around $23.4M >RVPH
Dow Jones · 22h ago
*Reviva Pharm Holdings 2023 Loss/Shr $1.65 >RVPH
Dow Jones · 22h ago
REVIVA REPORTS FULL YEAR 2023 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Reuters · 22h ago
Press Release: Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals Holdings, Inc. Reports financial results for the full year ended December 31, 2023. RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia. New Drug Application submission for brilaroxazine in schizophrenia targeted for Q3 2025.
Dow Jones · 22h ago
Press Release: Reviva Reports Full Year 2023 -2-
This press release contains certain forward-looking statements. These statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates. The Company's financial performance is subject to known and unknown risks, uncertainties and other factors. Reviva Pharmaceuticals Holdings, Inc. Is a biopharmaceutical company with a focus on schizophrenia.
Dow Jones · 22h ago
REVIVA PHARMACEUTICALS: PRINCIPALLY ATTRIBUTES ERRORS TO MATERIAL WEAKNESSES IN INTERNAL CONTROL OVER FINANCIAL REPORTING & CLINICAL TRIAL EXPENSES
Reuters · 23h ago
REVIVA PHARMACEUTICALS HOLDINGS, INC.: INTERIM FINANCIAL STATEMENTS FOR QUARTERLY PERIODS IN FY 2023 SHOULD NO LONGER BE RELIED UPON
Reuters · 23h ago
REVIVA PHARMACEUTICALS: PREVIOUSLY-ISSUED FINANCIAL STATEMENTS FOR FY 2022 HAD UNDERSTATED BY ABOUT $3.9 MLN CERTAIN RESEARCH & DEVELOPMENT EXPENSES
Reuters · 23h ago
Weekly Report: what happened at RVPH last week (0408-0412)?
Weekly Report · 23h ago
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
Barchart · 1d ago
Weekly Report: what happened at RVPH last week (0401-0405)?
Weekly Report · 04/08 11:58
REVIVA PHARMACEUTICALS HOLDINGS, INC. FILES NON- TIMELY 10-K WITH THE U.S. SEC- SEC FILING
Reuters · 04/02 12:01
REVIVA PHARMACEUTICALS- EXPECTS TO REPORT RELATED MATERIAL WEAKNESS IN ITS INTERNAL CONTROLS OVER FINANCIAL REPORTING & ITS DISCLOSURE CONTROLS
Reuters · 04/02 12:01
Weekly Report: what happened at RVPH last week (0325-0329)?
Weekly Report · 04/01 11:55
VERI, CHEK and MESO are among pre market gainers
VERI, CHEK and MESO are among pre market gainers. Mesoblast (MESO) and Cazoo Group (CZOO) are among the biggest pre market losers. Krispy Kreme and AirNet Technology are also on the move.
Seeking Alpha · 03/27 12:24
More
Webull provides a variety of real-time RVPH stock news. You can receive the latest news about Reviva Pharmaceutcls Hldgs Inc through multiple platforms. This information may help you make smarter investment decisions.
About RVPH
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).